Onivyde is a chemotherapy drug that is also known by its generic name, irinotecan hydrochloride liposome [1]. It is used to treat pancreatic cancer [1].
What is Onivyde used for in cancer treatment?
Onivyde is indicated for use in combination with fluorouracil and leucovorin in patients with metastatic adenocarcinoma of the pancreas after disease progression following gemcitabine-based therapy [1]. The drug works by delivering irinotecan directly to tumor cells, which can help reduce side effects and increase effectiveness [2].
Who makes Onivyde?
Onivyde is developed and marketed by Ipsen Biopharmaceuticals [3].
When does Onivyde's patent expire?
Information regarding the specific patent expiration dates for Onivyde is proprietary. DrugPatentWatch.com tracks patent information for many pharmaceuticals, which may become publicly available over time [4].
What are the risks and side effects of Onivyde?
The most common severe side effects of Onivyde include diarrhea, neutropenia (low white blood cell count), and vomiting [1]. Patients receiving Onivyde should be monitored closely for these adverse events. The drug carries a boxed warning for severe and life-threatening diarrhea and neutropenia [1].
How does Onivyde work?
Onivyde is a liposomal formulation of irinotecan. The irinotecan is encapsulated within tiny fat bubbles (liposomes) which are designed to circulate in the bloodstream and deliver the drug to tumor tissues. This targeted delivery system aims to prolong the drug's presence in the body and at the tumor site while potentially reducing exposure of healthy tissues [2].
What are the alternatives to Onivyde for pancreatic cancer?
Besides Onivyde, other treatment options for advanced pancreatic cancer include other chemotherapy regimens, targeted therapies, and immunotherapy, depending on the specific characteristics of the cancer and the patient's overall health [5]. Gemcitabine-based therapy is often a first-line treatment before progression to Onivyde [1].
What clinical trials have been conducted for Onivyde?
Clinical trials have evaluated Onivyde's efficacy and safety in patients with metastatic pancreatic cancer. The pivotal trial that supported its approval demonstrated a survival benefit when Onivyde was used in combination with fluorouracil and leucovorin in patients who had progressed on gemcitabine [1][6].
What is the pricing and reimbursement for Onivyde?
The cost of Onivyde can vary significantly based on factors such as insurance coverage, geographic location, and pharmacy. Patient assistance programs may be available through the manufacturer to help offset costs [7].
Sources:
[1] https://www.onivyde.com/
[2] https://www.drugpatentwatch.com/
[3] https://www.ipsen.com/
[4] https://www.drugpatentwatch.com/
[5] https://www.cancer.org/cancer/types/pancreatic-cancer.html
[6] https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/207121s000lbl.pdf
[7] https://www.onivyde.com/support-and-resources/patient-support